Kiadis Pharma BV, of Amsterdam, the Netherlands, said it initiated a collaboration to identify and characterize leukemia-specific T cells in Kiadis’ lead product, ATIR, that would be responsible for the graft-vs.-leukemia effect of the T-cell immunotherapy product.